Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025 (Katherine Davis/Axios)
Pathos AI’s valuation has risen 87.5% since May 2025.
The precision oncology company uses AI to develop cancer drugs. It said Friday it raised $237 million in Series E funding. The $3 billion post-money valuation compares with $1.6 billion in May 2025.
Techmeme's note
The precision oncology company uses AI to develop cancer drugs. It said Friday it raised $237 million in Series E funding. The $3 billion post-money valuation compares with $1.6 billion in May 2025.
Techmeme's note
score 8